Imeglimin

Drug Profile

Imeglimin

Alternative Names: EMD-387008

Latest Information Update: 26 Dec 2016

Price : $50

At a glance

  • Originator Merck KGaA
  • Developer Poxel
  • Class Amines; Antihyperglycaemics; Small molecules; Triazines
  • Mechanism of Action AMP activated protein kinase stimulants; Glucose modulators; Mitochondrial permeability transition pore inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 05 Dec 2016 Pharmacodynamics data from a preclinical trial in Type-2 diabetes mellitus released by Poxel
  • 01 Sep 2016 Poxel initiates a phase I safety trial in Healthy volunteers in United Kingdom (PO, Tablet) (NCT02924337)
  • 18 Jul 2016 Poxel plans a phase III trial for Type-2 diabetes mellitus in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top